The efficacy of five avirulent Edwardsiella tarda strains in a live vaccine against Edwardsiellosis in Japanese flounder, Paralichthys olivaceus

Fish & Shellfish Immunology
Tomokazu TakanoTakaji Iida

Abstract

We evaluated the tissue persistence and live vaccine efficacy of five avirulent Edwardsiella tarda strains (E22, SU100, SU117, SU138, and SU244) isolated from the Japanese eel (Anguilla japonica) and from the environment. The live vaccines, containing a single strain, were injected intraperitoneally into Japanese flounder (Paralichthys olivaceus). Viable bacteria from all the strains (excluding SU100) were recovered from trunk-kidney tissue 28 d post-injection. Japanese flounder inoculated with E22 had the highest relative percentage survival (RPS = 45%) in an artificial challenge with virulent E. tarda (NUF806). The serum of E22-vaccinated fish had a significantly higher agglutination titer against NUF806. In contrast, there was little or no increase in the agglutination titer of the fish that were inoculated with the remaining avirulent strains. Injection with avirulent E. tarda increased the expression of cytokine genes, including interleukin-1beta (IL-1beta), type 1 interferon (IFN), and IFN-gamma in head-kidney of the Japanese flounder.

References

Jan 1, 1990·Developmental and Comparative Immunology·A J Ainsworth, D X Chen
Dec 6, 2002·Diseases of Aquatic Organisms·Ramona T Skirpstunas, Thomas J Baldwin
Jun 26, 2003·Cancer Science·Akinori Takaoka, Tadatsugu Taniguchi
Nov 18, 2004·Immunological Reviews·Christian BogdanUlrike Schleicher
Apr 5, 2005·Immunology·Rajesh Ravindran, Stephen J McSorley
Jul 8, 2005·Microbiology·Y P TanK Y Leung
Jan 27, 2006·Journal of Fish Diseases·F PadrósS Crespo
Jul 14, 2007·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Marcelo B Sztein
Sep 14, 2007·Immunological Reviews·Lynne R ProstSamuel I Miller
Oct 8, 2008·Immunological Reviews·Miguel A TamMary Jo Wick

❮ Previous
Next ❯

Citations

Mar 16, 2013·Veterinary Immunology and Immunopathology·Masatoshi YamasakiAtsushi Yamamoto
Oct 6, 2012·Veterinary Research·Seong Bin ParkTae Sung Jung
Jul 17, 2012·Immunobiology·Manuel T Silva, Nazaré T Silva Pestana
Feb 22, 2012·Microbial Pathogenesis·Jong Earn YuHo Young Kang
Apr 29, 2015·Developmental and Comparative Immunology·Beibei ZhaoIkuo Hirono
Jul 24, 2014·Brazilian Journal of Biology = Revista Brasleira De Biologia·J D Biller-TakahashiE C Urbinati
Oct 17, 2018·Diseases of Aquatic Organisms·N BujánB Magariños
Jan 1, 2014·The Journal of General and Applied Microbiology·Thanh Trung CaoShih-Chu Chen

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antibodies: Agglutination

Antibody-mediated agglutination is the clumping of cells in the presence of antibody, which binds multiple cells together. This enhances the clearance of pathogens. Find the latest research on antibody-mediated agglutination here.

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.